MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press1810.17650/2782-3202-2021-1-1-87-92MEDICAL AND GENETIC CONSULTATION IN ONCOLOGIST’S PRACTICEМЕДИКО-ГЕНЕТИЧЕСКОЕ КОНСУЛЬТИРОВАНИЕ В ПРАКТИКЕ ВРАЧА-ОНКОЛОГАSurgical strategy in BRCA-associated breast cancer. Clinical caseХирургическая тактика при BRCA-ассоциированном раке молочной железы. Клинический случайhttps://orcid.org/0000-0002-1711-8334LyubchenkoL. N.ЛюбченкоЛ. Н.
Russian Federation

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia 

4 Koroleva St., Obninsk 249036, Russia 

Россия, 119991 Москва, ул. Трубецкая, 8, стр. 2

Россия, 249036 Обнинск, ул. Королева, 4

clingen@mail.ruhttps://orcid.org/0000-0002-2197-8863ZelenovaE. E.ЗеленоваЕ. Е.
Russian Federation

4 Koroleva St., Obninsk 249036, Russia 

Россия, 249036 Обнинск, ул. Королева, 4

SuglobovaA. A.СуглобоваА. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478, Russia 

Россия, 115478 Москва, Каширское шоссе, 24

ZhordaniyaK. I.ЖорданияК. И.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478, Russia 

Россия, 115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-5038-9307DavydovM. M.ДавыдовМ. М.
Russian Federation

Bld. 2, 8 Trubetskaya St., Moscow 119991, Russia 

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, Russia

Россия, 119991 Москва, ул. Трубецкая, 8, стр. 2

Россия, 43081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)National Medical Research Center of Radiology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииClinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»071220211187920209202107122021Copyright ©; 2021, ABV-PressCopyright ©; 2021, АБВ-пресс2021ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/18

 BRCA1 and BRCA2 genes mutations increase the risk of breast and ovarian cancer. Primary diagnosis of ovarian cancer is a complicated task due to the lack of effective screening programs, in this regard, medical and genetic counseling of patients with a family history is one of the important steps to develop an optimal strategy for the management of patients. In this article is presented an analysis of a clinical case of a patient with bilateral  metachronous breast and ovarian cancer with a detected germinal mutation5382insС in the BRCA1 gene. 

 Герминальные мутации в генах BRCA1 и BRCA2 ассоциированы с высоким риском развития одно- и двустороннего рака молочной железы и рака яичников. Первичная диагностика рака яичников является сложной  задачей ввиду отсутствия эффективных скрининговых  программ, в связи с этим медико-генетическое  консультирование пациентов с отягощенным семейным  анамнезом является одним из важных этапов, позволяющих  выработать оптимальную стратегию ведения пациентов. В данной работе представлен клинический случай  двустороннего метахронного рака молочных желез и яичников, ассоциированного с мутацией 5382insС в гене  BRCA1. 

gene BRCA1gene BRCA2ovarian cancerbreast cancermedical and genetic counselingген BRCA1ген BRCA2рак яичниковрак молочной железымедико-генетическое консультированиеThe state of oncological care to the population of Russia in 2017. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow: MNIOI n. a. P.A. Herzen – branch of the FSBI “NMIRC” of the Ministry of Health of Russia, 2018. 236 p. (In Russ.)Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2018. 236 с.Heemskerk-Gerritsen B.A., Seynaeve C., Van Asperen C.J. et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107(5):djv033. DOI: 10.1093/jnci/djv033.Brose M.S., Rebbeck T.R., Calzone K.A. et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94(18):1365–72. DOI: 10.1093/jnci/94.18.1365.Ford D., Easton D.F., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62(3):676–89. DOI: 10.1086/301749.Lakhani S.R., Manek S., Penault-Llorca F. et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10(7):2473–81. DOI: 10.1158/1078-0432.ccr-1029-3.Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 2014;289(2):241–6. DOI: 10.1007/s00404-013-3041-3.Bristow R.E., Powell M.A., Al-Hammadi N. et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 2013;105(11):823–32. DOI:10.1093/jnci/djt065.Bristow R.E., Chang J., Ziogas A. et al. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013;121(6):1226–34. DOI: 10.1097/AOG.0b013e3182922a17.Howell E.A., Egorova N., Hayes M.P. et al. Racial disparities in the treatment of advanced epithelial ovarian cancer. Obstet Gynecol 2013;122(5):1025–32. DOI: 10.1097/AOG.0b013e3182a92011.Maringe C., Walters S., Butler J. et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol 2012;127(1):75–82. DOI: 10.1016/j.ygyno.2012.06.033.Powell C.B., Swisher E.M., Cass I. et al. Long-term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013;129(2):364–71. DOI: 10.1016/j.ygyno.2013.01.029.Henderson J.T., Webber E.M., Sawaya G.F. et al. Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force. JAMA 2018;319(6):595–606. DOI: 10.1001/jama.2017.21421.Oliver Perez M.R., Magriñá J., Garcia A.T. Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: A reappraisal. Surg Oncol 2015;24(4):335–44. DOI: 10.1016/j.suronc.2015.09.008.Childers C.P., Childers K.K., Maggard-Gibbons M. et al. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol 2017;35(34):3800–6. DOI: 10.1200/JCO.2017.73.6314.D’Alonzo M., Piva E., Pecchio S. et al. Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. Clin Breast Cancer 2018;18(6):1361–6. DOI: 10.1016/j.clbc.2018.07.015.Finch A.P., Lubinski J., Moller P. et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32(15):1547–53. DOI: 10.1200/JCO.2013.53.2820.Sabiani L., Barrou J., Mathis J. et al. How to manage BRCA mutation carriers? Horm Mol Biol Clin Investig 2020;41(3) (Ahead of print). DOI: 10.1515/hmbci-2019-0065.Kotsopoulos J., Gronwald J., Karlan B.Y. et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carrier. JAMA Oncol 2018;4(8):1059–65. DOI: 10.1001/jamaoncol.2018.0211.Eleje G.U., Eke A.C., Ezebialu I.U. et al. Risk-reducing bilateral salpingooophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev 2018;8(8):CD012464. DOI: 10.1002/14651858.American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113(4):957–66.Hoskins P.J., Gotlieb W.H. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin 2017;67(6):493–506. DOI: 10.3322/caac.21408.Kramer L. Mixed reviews on removing fallopian tubes to prevent ovarian cancer. CMAJ 2013;185(9):E391–2. DOI: 10.1503/cmaj.109-4475.Bacha O.M., Gregoire J., Grondin K. et al. Effectiveness of risk-reducing salpingooophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gyncol Cancer 2012;22(6):974–8. DOI: 10.1097/IGC.0b013e318257b936.Iavazzo C., Gkegkes I.D., Vrachnis N. Primary peritoneal cancer in BRCA carriers after prophylacticbilateral salpingooophorectomy. J Turk Ger Gynecol Assoc 2016;17(2):73–6. DOI: 10.5152/jtgga.2016.15223.Levine D.A., Argenta P.A., Yee C.J. et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21(22):4222–7. DOI: 10.1200/JCO.2003.04.131.Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101(2):80–7. DOI: 10.1093/jnci/djn442.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2019 – July 30, 2018.Biglia N., Sgandurra P., Bounous V.E. et al. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Cancer Medical Science 2016;10:639. DOI: 10.3332/ecancer.2016.639.